3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
6
Phase 4
3
Phase 2
2
Phase 1/2
2
Phase EARLY_PHASE1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Lymphoma, Non-Hodgkin
4
Lymphoma, B-Cell
3
Carcinoma, Non-Small-Cell Lung
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Nasopharyngeal Neoplasms
1
Mesothelioma
1
Liver Neoplasms
1
Kidney Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Advanced Liver Cancers
1
Interventions
Dexamethasone
133
Lenalidomide
58
Bortezomib
56
Calcium Dobesilate
43
Melphalan
41
carfilzomib
38
pomalidomide
36
Cyclophosphamide
35
daratumumab
23
belantamab mafodotin
21
Peripheral Blood Stem Cell Transplantation
17
ixazomib
16
dexamethasone acetate
13
Filgrastim
13
Bendamustine Hydrochloride
13
fludarabine phosphate
12
fludarabine
12
dexamethasone 21-phosphate
12
Tacrolimus
12
auricularum
11
Whole-Body Irradiation
11
liposomal doxorubicin
10
iberdomide
10
Prednisone
10
venetoclax
9
selinexor
9
Mycophenolic Acid
9
pembrolizumab
8
isatuximab
8
Cyclosporine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Multiple Myeloma
×
tocilizumab
×
Clear all
NCT05535244
2026-05-07
CAMMA 2
Hoffmann-La Roche
Phase 1/2
Active not recruiting
90 enrolled
NCT05583617
2026-05-04
PLYCOM
Hoffmann-La Roche
Phase 1/2
Recruiting
200 enrolled